QR Code

Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL

Immunoglobulin E (IgE) plays a critical role in the allergen-initiated inflammatory pathway and thus serves as a viable therapeutic target in allergic or IgE-mediated diseases such as asthma. Omalizumab, an anti-IgE biologic, has been approved in the United States (US, 2003) and in the European Unio...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Francesco Menzella, MD, Jocelyne Just, MD, PhD, HDR, Inessa Schwab Sauerbeck, PhD, Claudia Mailaender, PhD, Fabiana Saccheri, PhD, Celine Thonnelier, Pharm D, Xavier Jaumont, MD, Laurence Mala, Pharm D
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Elsevier 2023-06-01
Rangatū:World Allergy Organization Journal
Ngā marau:
Immunoglobulin E
Omalizumab
Severe allergic asthma
Dosing
Urunga tuihono:http://www.sciencedirect.com/science/article/pii/S1939455123000479
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite